Blau Farmacêutica (BLAU3) Stock Overview
A pharmaceutical company provides drug products in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
BLAU3 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Blau Farmacêutica S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R$13.10 |
| 52 Week High | R$14.76 |
| 52 Week Low | R$11.48 |
| Beta | 0.40 |
| 1 Month Change | 5.22% |
| 3 Month Change | -5.89% |
| 1 Year Change | -9.41% |
| 3 Year Change | -46.05% |
| 5 Year Change | n/a |
| Change since IPO | -68.13% |
Recent News & Updates
Recent updates
Latin America Expansion And R&D Will Unlock New Markets
Strategic LatAm expansion and international partnerships are set to boost revenue and expand market share across multiple countries.Blau Farmacêutica (BVMF:BLAU3) Has A Pretty Healthy Balance Sheet
Mar 21
Does Blau Farmacêutica (BVMF:BLAU3) Have A Healthy Balance Sheet?
Dec 04Results: Blau Farmacêutica S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates
Nov 07Blau Farmacêutica S.A.'s (BVMF:BLAU3) 25% Share Price Surge Not Quite Adding Up
Nov 06Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings
Aug 29Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?
Jun 28Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop
Feb 01What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates
May 14Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next
Feb 24Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely
Oct 14Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)
Aug 17Shareholder Returns
| BLAU3 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | -2.2% | -2.6% | -2.5% |
| 1Y | -9.4% | 14.3% | 11.1% |
Return vs Industry: BLAU3 underperformed the BR Biotechs industry which returned 16.2% over the past year.
Return vs Market: BLAU3 underperformed the BR Market which returned 13.6% over the past year.
Price Volatility
| BLAU3 volatility | |
|---|---|
| BLAU3 Average Weekly Movement | 3.9% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in BR Market | 9.6% |
| 10% least volatile stocks in BR Market | 2.1% |
Stable Share Price: BLAU3 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: BLAU3's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 1,900 | Marcelo Hahn | www.blau.com |
Blau Farmacêutica S.A., a pharmaceutical company provides drug products in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States. Its products cover various areas, such as immunology, hematology, oncology, nephrology, infectology, and anesthesiology. The company offers uterine stimulator, antirheumatic, anaesthetics, antibiotics, feminine health care, biopharmaceuticals, oncologicals, hospital products, antivirals and antiretrovirals, biológicos, acid pump inhibitor, hemoderivatives, antithrombotic, and thrombolytics products.
Blau Farmacêutica S.A. Fundamentals Summary
| BLAU3 fundamental statistics | |
|---|---|
| Market cap | R$2.33b |
| Earnings (TTM) | R$324.56m |
| Revenue (TTM) | R$1.77b |
Is BLAU3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLAU3 income statement (TTM) | |
|---|---|
| Revenue | R$1.77b |
| Cost of Revenue | R$1.06b |
| Gross Profit | R$711.69m |
| Other Expenses | R$387.13m |
| Earnings | R$324.56m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.83 |
| Gross Margin | 40.23% |
| Net Profit Margin | 18.35% |
| Debt/Equity Ratio | 21.7% |
How did BLAU3 perform over the long term?
See historical performance and comparisonDividends
Does BLAU3 pay a reliable dividends?
See BLAU3 dividend history and benchmarks| Blau Farmacêutica dividend dates | |
|---|---|
| Ex Dividend Date | Dec 05 2025 |
| Dividend Pay Date | Dec 16 2025 |
| Days until Ex dividend | 6 days |
| Days until Dividend pay date | 5 days |
Does BLAU3 pay a reliable dividends?
See BLAU3 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/10 16:55 |
| End of Day Share Price | 2025/12/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Blau Farmacêutica S.A. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Valeria Parini | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |
| Marcio Osako | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |
| Frederico Mendes | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |